Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study

Raffaella Marcheselli; Luigi Marcheselli; Laura Cortesi; Alessia Bari; Claudia Cirilli; Samantha Pozzi; Paola Ferri; Martina Napolitano; Massimo Federico; Stefano Sacchi

추천

검색

자료유형: 학술저널

저자정보: Raffaella Marcheselli (University of Modena and Reggio Emilia) Luigi Marcheselli (University of Modena and Reggio Emilia) Laura Cortesi (University of Modena and Reggio Emilia) Alessia Bari (University of Modena and Reggio Emilia) Claudia Cirilli (Modena Cancer Registry) Samantha Pozzi (University of Modena and Reggio Emilia) Paola Ferri (University of Modena and Reggio Emilia) Martina Napolitano (University of Modena and Reggio Emilia) Massimo Federico (University of Modena and Reggio Emilia) Stefano Sacchi (University of Modena and Reggio Emilia)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.18 No.4

발행연도: 2015.1

수록면: 378 - 385 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Evolving therapies have improved the prognoses of patients with breast cancer; and currently, the number of longterm survivors is continuously increasing. However, these patients are at increased risk of developing a second cancer. Thus, late side effects are becoming an important issue. In this study, we aimed to investigate whether patient and tumor characteristics, and treatment type correlate with secondary tumor risk. Methods: This case-control study included 305 patients with a diagnosed second malignancy after almost 6 months after the diagnosis of primary breast cancer and 1,525 controls (ratio 1:5 of cases to controls) from a population-based cohort of 6,325 women. The control patients were randomly selected from the cohort and matched to the cases according to age at diagnosis, calendar period of diagnosis, disease stage, and time of followup. Results: BRCA1 or BRCA2 mutation, human epidermal growth factor receptor 2 (HER2)+ status, chemotherapy, and radiotherapy were related to increased risk of developing a second cancer, whereas hormonotherapy showed a protective effect. Chemotherapy, radiotherapy, and estrogenic receptor level <10% increased the risk of controlateral breast cancer. HER2+ status increased the risk of digestive system and thyroid tumors, while BRCA1 or BRCA2 mutation increased the risk of cancer in the genital system. Conclusion: Breast cancer survivors are exposed to an excess of risk of developing a second primary cancer. The development of excess of malignancies may be related either to patient and tumor characteristics, such as BRCA1 or BRCA2 mutation and HER2+ status, or to treatments factors.

참고문헌 (30)

참고문헌 신청

Hortobagyi GN / 2005 / The global breast cancer burden : variations in epidemiology and survival / Clin Breast Cancer 6:391~401

De Angelis R / 2014 / Cancer survival in Europe 1999-2007 by country and age : results of EUROCARE : 5-a population-based study / Lancet Oncol 15:23~34

Cortesi L / 2009 / Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer : a population-based study / Int J Gynecol Cancer 19:1358~1363

Mellemkjaer L / 2006 / Risk of second cancer among women with breast cancer / Int J Cancer 118:2285~2292

Mellemkjær L / 2011 / Risk of primary non-breast cancer after female breast cancer by age at diagnosis / Cancer Epidemiol Biomarkers Prev 20:1784~1792

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!